聚腺苷酸核糖聚合酶抑制治疗卵巢血管肉瘤：一例报告并文献复习
Angiosarcoma of the ovary treated with polyadenosine ribose polymerase Inhibition, a case report and review of the literature.
作者信息
Johnson Andrea M, Argenta Peter A
机构信息
Department of Obstetrics, Gynecology, and Women's Health, University of Minnesota, United States.
Division Gynecologic Oncology, Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, MN 55455, United States.
出版信息
Gynecol Oncol Rep. 2023 Aug 23;49:101264. doi: 10.1016/j.gore.2023.101264. eCollection 2023 Oct.
Abstract
•Primary angiosarcoma of the ovary historically has no standard treatment due to its rarity, and outcomes have been variable.•Olaparib may represent a viable treatment option for primary angiosarcoma of the ovary with a somatic BRCA mutation.•Next-generation sequencing may play an important component in treatment of very rare cancers to guide new or uncommon therapies.
摘要
•由于卵巢原发性血管肉瘤罕见，历史上一直没有标准治疗方法，治疗结果也各不相同。
•奥拉帕尼可能是治疗伴有体细胞BRCA突变的卵巢原发性血管肉瘤的一种可行治疗选择。
•新一代测序可能在极罕见癌症的治疗中发挥重要作用，以指导新的或不常见的治疗方法。
相似文献
1
Angiosarcoma of the ovary treated with polyadenosine ribose polymerase Inhibition, a case report and review of the literature.
Gynecol Oncol Rep. 2023 Aug 23;49:101264. doi: 10.1016/j.gore.2023.101264. eCollection 2023 Oct.
2
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study.
Int J Gynecol Cancer. 2021 Jul;31(7):1031-1036. doi: 10.1136/ijgc-2020-002343. Epub 2021 May 14.
3
Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study.
Drugs Real World Outcomes. 2023 Jun;10(2):207-213. doi: 10.1007/s40801-022-00349-9. Epub 2023 Jan 11.
4
Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
Oncologist. 2016 Aug;21(8):954-63. doi: 10.1634/theoncologist.2015-0268. Epub 2016 Jun 2.
5
The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation.
Hum Reprod. 2020 Aug 1;35(8):1864-1874. doi: 10.1093/humrep/deaa128.
6
Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups.
Int J Gynecol Cancer. 2022 Jun 6;32(6):799-803. doi: 10.1136/ijgc-2022-003435.
7
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol. 2021 Dec;22(12):1721-1731. doi: 10.1016/S1470-2045(21)00531-3. Epub 2021 Oct 26.
8
Pediatric Primary Ovarian Angiosarcoma: From Rarity to a Realization.
J Pediatr Adolesc Gynecol. 2018 Dec;31(6):629-631. doi: 10.1016/j.jpag.2018.08.008. Epub 2018 Sep 1.
9
Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
BMC Cancer. 2020 Mar 12;20(1):204. doi: 10.1186/s12885-020-6693-y.
10
GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer.
Future Sci OA. 2019 Jan 10;5(2):FSO370. doi: 10.4155/fsoa-2018-0107. eCollection 2019 Feb.
引用本文的文献
1
Atypical Pelvic Tumors in Children.
Cancers (Basel). 2025 Feb 12;17(4):619. doi: 10.3390/cancers17040619.
2
Ovarian Angiosarcoma With Intractable Intraperitoneal Hemorrhage: A Case Report and Review of the Literature.
Cureus. 2025 Jan 3;17(1):e76849. doi: 10.7759/cureus.76849. eCollection 2025 Jan.
3
Primary Ovarian Angiosarcoma: Diagnostic Challenges and Conundrums.
Discoveries (Craiova). 2024 Dec 31;12(4):e198. doi: 10.15190/d.2024.17. eCollection 2024 Oct-Dec.
本文引用的文献
1
Portuguese Consensus Recommendations for Next-Generation Sequencing of Lung Cancer, Rare Tumors, and Cancers of Unknown Primary Origin in Clinical Practice.
Acta Med Port. 2022 Sep 1;35(9):677-690. doi: 10.20344/amp.17680. Epub 2022 Jul 11.
2
Ovarian epithelioid angiosarcoma complicating pregnancy: a case report and review of the literature.
J Int Med Res. 2021 May;49(5):3000605211019641. doi: 10.1177/03000605211019641.
3
Primary ovarian angiosarcoma: a rare and recognizable ovarian tumor.
J Ovarian Res. 2021 Jan 28;14(1):21. doi: 10.1186/s13048-021-00771-7.
4
Pediatric ovarian angiosarcoma treated with systemic chemotherapy and cytoreductive surgery with heated intraperitoneal chemotherapy: Case report and review of therapy.
Pediatr Blood Cancer. 2019 Jul;66(7):e27753. doi: 10.1002/pbc.27753. Epub 2019 Apr 11.
5
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.
Lancet Oncol. 2018 Oct;19(10):1360-1371. doi: 10.1016/S1470-2045(18)30438-8. Epub 2018 Sep 11.
6
Pediatric Primary Ovarian Angiosarcoma: From Rarity to a Realization.
J Pediatr Adolesc Gynecol. 2018 Dec;31(6):629-631. doi: 10.1016/j.jpag.2018.08.008. Epub 2018 Sep 1.
7
Primary ovarian angiosarcoma in a 12- year -old girl: a case report of an exceptional localization in a context of limited resources country.
BMC Clin Pathol. 2017 Aug 24;17:16. doi: 10.1186/s12907-017-0056-x. eCollection 2017.
8
Gemcitabine-based regimen for primary ovarian angiosarcoma with MYC amplification.
Curr Oncol. 2014 Dec;21(6):e782-9. doi: 10.3747/co.21.2144.
9
Complete response after MAID treatment for advanced primary ovarian angiosarcoma: case report and literature review.
Eur J Gynaecol Oncol. 2014;35(3):318-21.
10
Ovarian angiosarcoma: Extended survival following optimal cytoreductive surgery and adjuvant chemotherapy.
Gynecol Oncol Case Rep. 2012 Dec 20;4:23-5. doi: 10.1016/j.gynor.2012.12.006. eCollection 2012.
Zotero 插件